Middle East & Africa Biosimilars Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis by Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)

No. of Pages: 158    |    Report Code: BMIRE00028364    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Middle East & Africa Biosimilars Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Middle East & Africa Biosimilars Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Middle East & Africa Biosimilars Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1 Rising demand for biosimilars due to cost-effectiveness
  • 5.1.2 Expanding use of biosimilars in oncology and immunology
5.2 Market Opportunities
  • 5.2.1 Adoption of biosimilars to lower healthcare costs
  • 5.2.2 Expansion into emerging markets with biosimilar drugs
5.3 Future Trends
  • 5.3.1 Growing adoption of biosimilars
  • 5.3.2 Support for biosimilar approvals
5.4 Impact of Drivers and Restraints

6. Middle East & Africa Biosimilars Market Regional Analysis

6.1 Middle East & Africa Biosimilars Market Overview
6.2 Middle East & Africa Biosimilars Market Revenue 2020-2028 (US$ Million)
6.3 Middle East & Africa Biosimilars Market Forecast Analysis

7. Middle East & Africa Biosimilars Market Analysis – by Disease Indication

7.1 Cancer
  • 7.1.1 Overview
  • 7.1.2 Cancer: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Diabetes
  • 7.2.1 Overview
  • 7.2.2 Diabetes: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Autoimmune Diseases
  • 7.3.1 Overview
  • 7.3.2 Autoimmune Diseases: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Other Diseases
  • 7.4.1 Overview
  • 7.4.2 Other Diseases: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2031 (US$ Million)

8. Middle East & Africa Biosimilars Market Analysis – by Drug Class

8.1 Granulocyte Colony-Stimulating Factors
  • 8.1.1 Overview
  • 8.1.2 Granulocyte Colony-Stimulating Factors: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Human Growth Hormone
  • 8.2.1 Overview
  • 8.2.2 Human Growth Hormone: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Insulin
  • 8.3.1 Overview
  • 8.3.2 Insulin: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.4 TNF Blockers & Monoclonal Antibodies
  • 8.4.1 Overview
  • 8.4.2 TNF Blockers & Monoclonal Antibodies: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Erythropoietin-Stimulating Agents
  • 8.5.1 Overview
  • 8.5.2 Erythropoietin-Stimulating Agents: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9. Middle East & Africa Biosimilars Market Analysis – by Route of Administration

9.1 Intravenous
  • 9.1.1 Overview
  • 9.1.2 Erythropoietin-Stimulating Agents: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Subcutaneous
  • 9.2.1 Overview
  • 9.2.2 Erythropoietin-Stimulating Agents: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10. Middle East & Africa Biosimilars Market – Middle East and Africa Analysis

10.1 Middle East and Africa
  • 10.1.1 Middle East & Africa Biosimilars Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 10.1.1.1 Middle East & Africa Biosimilars Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 South Africa: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 South Africa: Middle East & Africa Biosimilars Market Breakdown, by Disease Indication
    • 10.1.1.1.2 South Africa: Middle East & Africa Biosimilars Market Breakdown, by Drug Class
    • 10.1.1.1.3 South Africa: Middle East & Africa Biosimilars Market Breakdown, by Route of Administration
  • 10.1.1.2 Saudi Arabia: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Saudi Arabia: Middle East & Africa Biosimilars Market Breakdown, by Disease Indication
    • 10.1.1.2.2 Saudi Arabia: Middle East & Africa Biosimilars Market Breakdown, by Drug Class
    • 10.1.1.2.3 Saudi Arabia: Middle East & Africa Biosimilars Market Breakdown, by Route of Administration
  • 10.1.1.3 UAE: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 UAE: Middle East & Africa Biosimilars Market Breakdown, by Disease Indication
    • 10.1.1.3.2 UAE: Middle East & Africa Biosimilars Market Breakdown, by Drug Class
    • 10.1.1.3.3 UAE: Middle East & Africa Biosimilars Market Breakdown, by Route of Administration
  • 10.1.1.4 Rest of Middle East and Africa: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Rest of Middle East and Africa: Middle East & Africa Biosimilars Market Breakdown, by Disease Indication
    • 10.1.1.4.2 Rest of Middle East and Africa: Middle East & Africa Biosimilars Market Breakdown, by Drug Class
    • 10.1.1.4.3 Rest of Middle East and Africa: Middle East & Africa Biosimilars Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Middle East & Africa Biosimilars Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Amgen Inc
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Sanofi SA
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Biocon Ltd
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Eli Lilly and Co
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Sandoz AG
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Teva Pharmaceutical Industries Ltd
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Pfizer Inc
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Dr. Reddy's Laboratories Ltd
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - M Market

  1. Amgen Inc
  2. Sanofi SA  
  3. Biocon Ltd
  4. Eli Lilly and Co
  5. Sandoz AG
  6. Teva Pharmaceutical Industries Ltd
  7. Pfizer Inc
  8. Dr. Reddy's Laboratories Ltd
middle-east-and-africa-biosimilars-market